Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in two upcoming investor conferences in New York:
1. H.C. Wainwright 26th Annual Global Investment Conference: Formal presentation on September 9, 2024, at 8:00 am ET
2. Baird Global Healthcare Conference: Fireside chat on September 10, 2024, at 8:30 am ET
The Arbutus management team will participate in and host one-on-one meetings at both events. Interested parties can access live webcasts of the presentation and fireside chat through the company's investor relations website. Archived replays will be available for a time after the events.
Arbutus Biopharma (Nasdaq: ABUS), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di una cura funzionale per l'infezione cronica da virus dell'epatite B (cHBV), ha annunciato la sua partecipazione a due prossime conferenze per investitori a New York:
1. 26ª Conferenza annuale globale sugli investimenti H.C. Wainwright: Presentazione formale il 9 settembre 2024, alle 8:00 am ET
2. Conferenza globale sulla salute Baird: Discussione informale il 10 settembre 2024, alle 8:30 am ET
Il team di gestione di Arbutus parteciperà e ospiterà incontri individuali a entrambi gli eventi. Le parti interessate possono accedere alle dirette delle presentazioni e delle discussioni informali tramite il sito web delle relazioni con gli investitori dell'azienda. Le riproduzioni archiviate saranno disponibili per un periodo dopo gli eventi.
Arbutus Biopharma (Nasdaq: ABUS), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de una cura funcional para la infección crónica por el virus de la hepatitis B (cHBV), ha anunciado su participación en dos próximas conferencias para inversores en Nueva York:
1. 26ª Conferencia anual global de inversión H.C. Wainwright: Presentación formal el 9 de septiembre de 2024, a las 8:00 am ET
2. Conferencia global de salud de Baird: Charla junto a la chimenea el 10 de septiembre de 2024, a las 8:30 am ET
El equipo de gestión de Arbutus participará y organizará reuniones individuales en ambos eventos. Las partes interesadas pueden acceder a las transmisiones en vivo de la presentación y la charla junto a la chimenea a través del sitio web de relaciones con inversores de la empresa. Las repeticiones archivadas estarán disponibles por un tiempo después de los eventos.
Arbutus Biopharma (Nasdaq: ABUS), 만성 B형 간염 바이러스(cHBV) 감염을 위한 기능적 치료제를 개발하는 데 초점을 맞춘 임상 단계의 생명공학 회사가 뉴욕에서 열리는 두 개의 투자자 컨퍼런스에 참가한다고 발표했습니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스: 2024년 9월 9일 오전 8시(ET) 공식 발표
2. Baird 글로벌 헬스케어 컨퍼런스: 2024년 9월 10일 오전 8시 30분(ET) 불가운담
Arbutus 경영팀은 두 이벤트에 참여하고 개별 미팅을 주최할 예정입니다. 관심 있는 당사자는 회사의 투자자 관계 웹사이트를 통해 발표 및 불가운담의 생중계를 시청할 수 있습니다. 이벤트 후 일정 기간 동안 보관된 재생도 이용할 수 있습니다.
Arbutus Biopharma (Nasdaq: ABUS), une entreprise biopharmaceutique en phase clinique axée sur le développement d'un traitement fonctionnel pour l'infection chronique par le virus de l'hépatite B (cHBV), a annoncé sa participation à deux prochaines conférences pour investisseurs à New York :
1. 26e conférence annuelle mondiale sur les investissements H.C. Wainwright : Présentation formelle le 9 septembre 2024, à 8h00 ET
2. Conférence mondiale sur la santé de Baird : Discussion informelle le 10 septembre 2024, à 8h30 ET
L'équipe de direction d'Arbutus participera et organisera des réunions individuelles lors des deux événements. Les parties intéressées peuvent accéder aux diffusions en direct de la présentation et de la discussion via le site de relations investisseurs de l'entreprise. Des rediffusions archivées seront disponibles pendant un certain temps après les événements.
Arbutus Biopharma (Nasdaq: ABUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer funktionalen Heilung für die chronische Hepatitis-B-Virus (cHBV)-Infektion konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen in New York angekündigt:
1. 26. jährliche globale Investmentkonferenz von H.C. Wainwright: Formelle Präsentation am 9. September 2024 um 8:00 Uhr ET
2. Baird globale Gesundheitskonferenz: Gespräch am Feuer am 10. September 2024 um 8:30 Uhr ET
Das Management-Team von Arbutus wird an beiden Veranstaltungen teilnehmen und Einzelgespräche durchführen. Interessierte können die Live-Übertragungen der Präsentation und des Gesprächs über die Investor-Relations-Website des Unternehmens abrufen. Archivierte Wiederholungen werden für eine bestimmte Zeit nach den Veranstaltungen verfügbar sein.
- None.
- None.
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
- H.C. Wainwright 26th Annual Global Investment Conference: Formal Presentation on September 9, 2024 at 8:00 am ET
- Baird Global Healthcare Conference: Fireside Chat on September 10, 2024 at 8:30 am ET
To access the live webcast of the presentation and fireside chat please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When is Arbutus Biopharma (ABUS) presenting at the H.C. Wainwright Global Investment Conference?
What type of event is Arbutus Biopharma (ABUS) participating in at the Baird Global Healthcare Conference?
Where can investors access the webcasts of Arbutus Biopharma's (ABUS) conference presentations?
What is the main focus of Arbutus Biopharma's (ABUS) research and development?
